Just the beginning | Thread profile

The volume over the past couple of days is telling us something.......Very interesting.....

Wow babe, waxing poetic on the ADLS message board! And not the first time, either. I gotta say, this stock is looking and smelling worse as each day passes. Talk about an aroma too inviting to ignore...to a dung beetle!

Nice find. the comparison to Adls is unccanny, especially if you overlap the 12 month charts. IOMI had low volume, all but one day preceding the buyout announcement. There was no warning. The stock had increased but a few "good news" press release developments were the force there. 2 months ago the stock was at $1/ market cap 25 million, a "going concern" , on a 2...

http://www.fool.com/investing/high-growt... Glaxo's Three-Quarter-Billion-Dollar Gamble By Brian Lawler April 23, 2008 3 Recommendations Never a company to shy away from acquiring new drugs via partnerships and acquisitions, GlaxoSmithKline (NYSE: GSK) announced last night that it would acquire development stage drugmaker Sirtris Pharmaceuticals (Nasdaq: SIRT)....

Cancer Drugs Pfizer Goes Bargain Hunting Matthew Herper, 04.16.08, 5:39 PM ET Pfizer is following a new strategy for making biotech deals: bargain hunting. In the past six months, Pfizer (nyse: PFE - news - people ), which has $25 billion in cash, has done two $200 million acquisitions. This afternoon, after market close, the company announced another: a ...

$150 million market cap for Avant, which was before the Pfizer deal. $150 market cap for ADLS would put the stock at $3. If, and this is a big if, we get a deal for Ceth and ALS-357 this year, ADLS may see $3-$5 sooner than we think. I believe the upside potential here is much greater than the downside risk.

Look at IOMI's pipeline. Their leading drug candidate treats "travellers diarrhea", which according to their website has a $700 million market opportunity. They are JUST COMPLETING Phase II studies. IOMI gets taken out at $189 million. OK, CAP is a $14 billion worldwide market. CETH has completed Phase III at QT studies with flying colors. $189 million buyout of ADLS would put the ...

You should read some of the harsh posting on IOMI pre march 15th. They were out to lynch management! Heavy criticism towards managements silence and not being able to get a deal done. sound familiar. IOMI message board: We are now approaching the 7 month mark re: the ETEC results releaseQuestions: 1)How long does it take to cut an adequate...

Well, as I said in an earlier post, IOMI inked a $189 million take out with their main drug candidate still in Phase II trials. ADLS has three successful clinical trials and a QT study for CAP under their belt AND 100% success rate against inhalation Anthrax. ADLS should be able to ink $200-$250 million deal with their pipeline.

That's why I'm here with a little chunk of the money I made from Iomai...